title: Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms.
abstract: BACKGROUND
  Selegiline orally disintegrating tablet (ODT; Zelapar) is a selective monoamine oxidase B inhibitor developed as an adjunct to levodopa (LD) for Parkinson disease. Most patients on long-term LD therapy eventually experience deterioration at the end of the LD dosing interval, with predictable "wearing off" and "on-off" fluctuations.
  
  
  METHODS
  We conducted a 12-week, double-blind, placebo-controlled, parallel-design trial of selegiline ODT. The primary efficacy point was reduction in the percentage of average daily "off" time. Secondary measures included reductions in daily off hours and total daily off time, Clinical Global Impressions-Improvement (CGI-I), and Patient Global Impression-Improvement (PGI-I). Patients on LD received selegiline ODT (1.25 mg/d for 6 weeks, then 2.5 mg/d for 6 weeks) or placebo. Safety and tolerability were measured.
  
  
  RESULTS
  The intent-to-treat population included 98 patients receiving selegiline ODT and 50 patients receiving placebo. Combined efficacy results for weeks 10 and 12 revealed an 11.6% reduction in percentage of daily off time for selegiline ODT versus a 9.8% reduction for placebo (NS). PGI-I detected a statistically significant difference between treatment groups in favor of selegiline ODT (P = 0.02), whereas CGI-I detected a strong trend toward improvement (P = 0.06). Selegiline ODT was safe and well tolerated.
  
  
  CONCLUSIONS
  This study showed no significant difference in improvement in percentage of off time with selegiline ODT versus placebo. Some clinical impressions (e.g., PGI-I, CGI-I) improved. This result contrasts with an identically designed study that showed a significant improvement in off time with selegiline ODT. A combined analysis of both studies suggested overall efficacy.
authors.affiliation: Baylor College of Medicine, Department of Neurology, 6550 Fannin, Houston, TX 77030, USA. wondo@bcm.tmc.edu
authors.forename: William G
authors.initials: WG
authors.lastname: Ondo
authors.forename: Kapil D
authors.initials: KD
authors.lastname: Sethi
authors.forename: Greg
authors.initials: G
authors.lastname: Kricorian
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004341:Drug Evaluation; D015673:Fatigue Syndrome, Chronic / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy*; D012642:Selegiline / Q000008:administration & dosage*; D012720:Severity of Illness Index; D013607:Tablets / Q000008:administration & dosage
chemical_list: D000978:Antiparkinson Agents; D013607:Tablets; D012642:Selegiline